Royalty Pharma PLC 8-K filings

Royalty Pharma has entered into an agreement to issue and sell $1.5 billion in senior notes across three tranches, with the offering expected to close on June 10, 2024.

Royalty Pharma stands to gain from positive Phase 3 trial results for seltorexant, a potential treatment for major depressive disorder with insomnia, which could generate significant royalty revenue.

Royalty Pharma announced a 14% increase in Royalty Receipts for the first quarter of 2024, driven by strong portfolio performance, and confirmed its full-year 2024 guidance.

Royalty Pharma announced its fourth quarter and full year 2023 financial results, highlighting a 9% increase in portfolio receipts for the year and providing 2024 guidance.

Royalty Pharma stands to gain from Novartis' acquisition of MorphoSys, with existing royalty agreements and equity holdings set to increase in value.